A new ligand for targeted drug delivery to tumor stromal cells

Journal of Controlled Release

Volumn 145, Issue 2, 2010, Pages 75-

  Park, Kinam ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HUMAN SERUM ALBUMIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

CELL HETEROGENEITY; CELL POPULATION; COLON CARCINOMA; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; EDITORIAL; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PERICYTE; PRIORITY JOURNAL; STROMA; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FIBROBLASTS; HUMANS; LIGANDS; MICE; NEOPLASMS; PERICYTES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; STROMAL CELLS;

EID: 77954141982     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.001     Document Type: Editorial

References (2)

1. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer. 2004, 4:839-849.
2. Prakash J., de Jong E., Post E., Gouw A.S.H., Beljaars L., Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J. Control. Release 2010, 145:91-101.